Home Economy News FDA clears Pulse Biosciences’ soft tissue ablation system

FDA clears Pulse Biosciences’ soft tissue ablation system


FDA clears Pulse Biosciences’ soft tissue ablation system By Investing.com

Breaking News


EditorBrando BricchiEconomy

Published Mar 08, 2024 01:22PM ET

HAYWARD, Calif. – Pulse Biosciences, Inc. (NASDAQ:PLSE), a bioelectric medicine company, has announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX Nanosecond Pulsed Field Ablation (nsPFA) Percutaneous Electrode System. This system is intended for use in the ablation of soft tissue during percutaneous and intraoperative surgical procedures.

The CellFX nsPFA Percutaneous Electrode System employs a percutaneous needle electrode that works with the company’s CellFX nsPFA Console. The technology behind this system is designed to precisely remove cellular tissue without affecting noncellular structures or causing thermal necrosis, which is the death of cells due to excessive heat.

The FDA clearance marks a significant milestone for the company in the surgical field, providing a new set of clinical applications for its proprietary technology. Kevin Danahy, President and CEO of Pulse Biosciences, expressed pride in the company’s teams for their dedication to making nsPFA technology available to physicians and patients. He also noted the company’s readiness for initiating training and commercialization programs in the upcoming weeks.

Dr. Ralph P. Tufano, Senior Advisor and Chair of the Scientific Advisory Board at Pulse Biosciences, emphasized the system’s promise as a minimally invasive treatment option. He cited early study results that demonstrated rapid clearance of ablated tissue and the absence of thermal damage or scarring.

Pulse Biosciences is focused on developing its CellFX nsPFA technology for various medical applications, including the treatment of atrial fibrillation. The company’s technology aims to improve the quality of life for patients by delivering nanosecond pulses of electrical energy to clear cells non-thermally while sparing adjacent noncellular tissue.

This news is based on a press release statement from Pulse Biosciences, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

FDA clears Pulse Biosciences’ soft tissue ablation system

Our Apps

Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information

© 2007-2024 Fusion Media Limited. All Rights Reserved.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Related News